ShiraTronics is developing an implantable neuromodulation therapy for people with treatment-resistant chronic migraine. The company sits within therapeutic neuromodulation, with a focused application in headache medicine and patients who continue to experience high migraine burden despite existing preventive therapies.

The ShiraTronics Migraine Therapy System is implanted beneath the skin in the head and delivers electrical stimulation to nerve pathways associated with migraine pain. Public materials describe stimulation of targeted nerves, including occipital and supraorbital pathways, with therapy designed to reduce headache frequency, severity, and duration.

ShiraTronics targets adults with treatment-resistant chronic migraine through an FDA-approved IDE pivotal study in the United States and Australia. The company raised $66 million in Series B financing to support the RELIEV-CM2 pivotal trial, pursue FDA premarket approval, and prepare for initial commercialization.